Drug Trial News

RSS

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

The first detailed results from AbbVie's pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4.

4 Mar 2014

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it received regulatory approval to begin a Phase 2a clinical trial of ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis B virus (HBV) infection.

4 Mar 2014

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.

4 Mar 2014

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL).

3 Mar 2014

Phase III studies show tiotropium delivered via Respimat inhaler proves effective in asthma patients

Boehringer Ingelheim today announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® inhaler was effective and well tolerated in patients across asthma severities.

3 Mar 2014

Actavis files ANDA with FDA to market Colchicine Tablets USP

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg.

3 Mar 2014

Randomized trial of bevacizumab for glioblastoma shows disappointing results

"The results of this study are counter to most expectations," said Dr. Brachman, Director of Radiation Oncology at Barrow and St. Joseph's. "Bevacizumab had been shown in earlier studies to be an effective drug in the treatment of patients with recurrent disease. But, on newly diagnosed patients, it did not, in fact, prolong survival."

3 Mar 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

Celsion reports positive interim data from Phase 2 DIGNITY Trial of ThermoDox in RCWBC

Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer.

28 Feb 2014

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Adocia announces today positive preliminary results for the first clinical trial on an innovative formulation combining insulin analog Glargine (Lantus, Sanofi), the gold standard basal insulin, with a rapid-acting insulin analog, Lispro (Humalog, Eli Lilly) using Adocia's BioChaperone technology.

27 Feb 2014

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint.

27 Feb 2014

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis.

27 Feb 2014

Phase 2 trial results show GPB reduces hepatic encephalopathy episodes in patients with cirrhosis

Phase 2 trial results published in the March issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, suggests the potential for Glycerol Phenylbutyrate (GPB) to reduce hepatic encephalopathy episodes in patients with cirrhosis, with a safety profile similar to placebo.

27 Feb 2014

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Biothera presented results of its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) this past weekend to top clinicians and scientists at the invitation-only International Association for the Study of Lung Cancer meeting on targeted therapies in Santa Monica, CA.

26 Feb 2014

Isis Pharmaceuticals provides update on ISIS-SMNRx Phase 2 study in infants with SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open label, multiple dose Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy (SMA).

25 Feb 2014

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

The final results from an international clinical trial involving nearly 2,000 patients with Crohn's disease support the use of a new management strategy referred to as accelerated step-care as a best practice for the care of active Crohn's disease.

24 Feb 2014

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has completed dosing of its Phase 2 clinical trial of GCS-100 for the treatment of chronic kidney disease ("CKD") and has collected the final data for evaluation of the primary endpoint.

23 Feb 2014

Avastin can prolong the lives of women with advanced cervical cancer

New data showing cancer treatment Avastin (bevacizumab) can extend the lives of women with advanced cervical cancer compared to chemotherapy alone has been published in the New England Journal of Medicine.

21 Feb 2014

Drug Trial News

AbbVie's PEARL-III study meets primary, secondary endpoints in patients with chronic GT1b HCV infection

Arrowhead receives approval to initiate Phase 2a clinical trial of ARC-520 for chronic HBV infection

Intra-Cellular Therapies initiates Phase I/II clinical trial to evaluate pharmacokinetics in patients with dementia

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Cell Therapeutics initiates Phase 3 clinical trial to evaluate pacritinib in patients with myelofibrosis

Phase III studies show tiotropium delivered via Respimat inhaler proves effective in asthma patients

Actavis files ANDA with FDA to market Colchicine Tablets USP

Randomized trial of bevacizumab for glioblastoma shows disappointing results

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Celsion reports positive interim data from Phase 2 DIGNITY Trial of ThermoDox in RCWBC

Adocia reports positive preliminary results for first clinical trial of BioChaperone Combo

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Altheus Therapeutics completes dosing of ZA201 in Phase 2 trial of Zoenasa for ulcerative colitis

Phase 2 trial results show GPB reduces hepatic encephalopathy episodes in patients with cirrhosis

Biothera’s Phase 2b clinical trial in NSCLC presented at International Association for the Study of Lung Cancer

Isis Pharmaceuticals provides update on ISIS-SMNRx Phase 2 study in infants with SMA

REACT clinical trial provides valuable new insights for community gastroenterologists that benefit patients

LJPC completes dosing in Phase 2 clinical trial of GCS-100 for treatment of chronic kidney disease

Avastin can prolong the lives of women with advanced cervical cancer

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News